- Home
- TBI vs CCCC Comparison
TBI vs CCCC Comparison
Compare TBI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBI
- CCCC
- Stock Information
- Founded
- TBI 1985
- CCCC 2015
- Country
- TBI United States
- CCCC United States
- Employees
- TBI N/A
- CCCC N/A
- Industry
- TBI Professional Services
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- TBI Consumer Discretionary
- CCCC Health Care
- Exchange
- TBI Nasdaq
- CCCC Nasdaq
- Market Cap
- TBI 127.9M
- CCCC 115.0M
- IPO Year
- TBI 1996
- CCCC 2020
- Fundamental
- Price
- TBI $4.41
- CCCC $1.47
- Analyst Decision
- TBI Buy
- CCCC Buy
- Analyst Count
- TBI 2
- CCCC 4
- Target Price
- TBI $11.50
- CCCC $12.50
- AVG Volume (30 Days)
- TBI 267.2K
- CCCC 1.3M
- Earning Date
- TBI 05-05-2025
- CCCC 05-07-2025
- Dividend Yield
- TBI N/A
- CCCC N/A
- EPS Growth
- TBI N/A
- CCCC N/A
- EPS
- TBI N/A
- CCCC N/A
- Revenue
- TBI $1,534,794,000.00
- CCCC $39,783,000.00
- Revenue This Year
- TBI N/A
- CCCC N/A
- Revenue Next Year
- TBI $9.22
- CCCC $36.31
- P/E Ratio
- TBI N/A
- CCCC N/A
- Revenue Growth
- TBI N/A
- CCCC 98.56
- 52 Week Low
- TBI $3.45
- CCCC $1.09
- 52 Week High
- TBI $12.29
- CCCC $7.66
- Technical
- Relative Strength Index (RSI)
- TBI 46.72
- CCCC 44.60
- Support Level
- TBI $3.45
- CCCC $1.42
- Resistance Level
- TBI $4.62
- CCCC $1.69
- Average True Range (ATR)
- TBI 0.30
- CCCC 0.16
- MACD
- TBI 0.05
- CCCC 0.03
- Stochastic Oscillator
- TBI 80.00
- CCCC 27.27
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.